What Happens to Testosterone in Perimenopause?

What Happens to Testosterone in Perimenopause?

Testosterone declines gradually throughout perimenopause, falling roughly 50% between a woman's 20s and her early 50s — but the drop isn't sudden or tied to any single hormonal event. Most people notice effects only when levels cross a personal threshold, and some never experience symptoms at all. Those already under chronic stress or with suboptimal nutrition tend to feel the shift earliest and most sharply.

How Testosterone Changes During Perimenopause

Testosterone in women comes from two main sources: the ovaries and the adrenal glands. Unlike estrogen, which swings dramatically during the perimenopausal transition, testosterone tends to decline more steadily starting in the late 30s and continuing through the 50s. By the time menopause is confirmed, total testosterone is often half what it was in peak reproductive years (Davison et al., Journal of Clinical Endocrinology & Metabolism 2005; PMID: 15509641).

What makes this tricky is that total testosterone alone is a poor measure of how much is actually available to tissues. Most circulating testosterone is bound to sex hormone-binding globulin (SHBG) and albumin; only free testosterone — roughly 1–3% of the total — is biologically active. During perimenopause, SHBG levels can fluctuate significantly as estrogen shifts, meaning free testosterone levels don't always track predictably with total testosterone. A woman can have a "normal" total testosterone and still experience symptoms of deficiency if SHBG is elevated and binding most of it. You can read more about how SHBG behaves during this transition in our article on what happens to SHBG levels in perimenopause.

The ovarian contribution to testosterone production also changes in a non-linear way. In the early perimenopausal years, the ovaries continue producing androgens even as estrogen output becomes erratic. After menopause, the ovarian stroma actually continues to secrete some testosterone — which is one reason postmenopausal women aren't completely androgen-deficient. The adrenal glands, via dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS), contribute significantly to the androgen pool throughout this period, but adrenal androgen output also declines with age in a process called adrenopause, which begins as early as the late 20s and is largely independent of ovarian function (Labrie et al., Journal of Steroid Biochemistry and Molecular Biology 2003; PMID: 14623515).

Signs of Low Testosterone in Perimenopause

Low testosterone in perimenopausal women presents differently than it does in men, and is frequently misread as depression, burnout, or generalized perimenopause symptoms. The most consistent clinical signs include:

• Reduced libido — often the first and most distressing symptom. Multiple randomized controlled trials have shown a direct relationship between free testosterone levels and sexual desire in women (Davis et al., Menopause 2008; PMID: 18978637).
• Fatigue and low motivation — testosterone supports mitochondrial function and red blood cell production; when it drops, energy generation at the cellular level becomes less efficient.
• Loss of lean muscle mass — testosterone is anabolic. Perimenopausal women who notice increased difficulty maintaining muscle despite consistent training may be experiencing androgen-related changes.
• Mood instability and low mood — androgens influence dopaminergic and serotonergic signaling. Testosterone receptors are expressed in limbic brain regions, and low levels correlate with depressive symptoms independent of estrogen status.
• Cognitive fog and difficulty concentrating — animal and observational human data suggest testosterone has neuroprotective roles; its decline may contribute to the brain fog commonly reported in perimenopause.
• Reduced bone density — testosterone, like estrogen, has direct effects on osteoblast activity. This partially explains why bone loss in perimenopause isn't fully reversed by estrogen-only therapy. For a deeper look at bone changes during this period, see our article on what happens to bone density in perimenopause.
• Thinning hair and dry skin — androgenic support of hair follicle activity drops alongside testosterone; paradoxically, some women experience hair loss from both low androgens and from the relative androgenic dominance that can emerge when estrogen falls faster than testosterone.

If you are experiencing low libido during perimenopause, testosterone status is one of the first hormonal variables worth investigating via bloodwork.

Signs of High Testosterone in Perimenopause

While deficiency is more common, some women experience a period of relative androgen excess in early perimenopause. This typically occurs when estrogen begins to fall faster than testosterone, temporarily shifting the estrogen-to-testosterone ratio. It can also occur with conditions like polycystic ovary syndrome (PCOS), adrenal hyperactivity, or insulin resistance — all of which become more common as metabolic health changes in midlife.

Signs of high testosterone include:

• Acne — particularly along the jawline and chin, driven by androgenic stimulation of sebaceous glands.
• Increased facial or body hair (hirsutism) — testosterone is converted peripherally to dihydrotestosterone (DHT), which stimulates terminal hair growth in androgen-sensitive follicles.
• Scalp hair thinning or androgenic alopecia — paradoxically, high DHT can miniaturize scalp follicles even as body hair increases.
• Oily skin — sebum production is androgen-dependent.
• Irritability, aggression, or mood changes — though these overlap significantly with general perimenopausal mood symptoms.
• Menstrual irregularities — elevated androgens can disrupt the LH/FSH signaling cascade that governs cycle regularity. See our article on what happens to LH levels in perimenopause for context on how this signaling changes.

High testosterone in perimenopause warrants medical evaluation. It can indicate adrenal pathology, ovarian tumors (rare), or metabolic conditions like insulin resistance. What is a normal testosterone level in perimenopause covers reference ranges in detail — but broadly, total testosterone in women typically falls between 15–70 ng/dL, and anything consistently above that range alongside symptoms should be investigated.

How Stress Amplifies Testosterone Decline

Chronic psychological and physiological stress is one of the most underappreciated drivers of androgen depletion in perimenopausal women. The mechanism is well characterized: elevated cortisol, produced by the adrenal cortex in response to stress, directly suppresses gonadal and adrenal androgen production via inhibition of the hypothalamic-pituitary-gonadal (HPG) axis. This is sometimes called "cortisol steal" — though the more precise mechanism is competitive substrate utilization and HPG suppression rather than actual pregnenolone diversion.

In one study of healthy women, acute psychological stress significantly reduced testosterone and DHEAS levels within hours, with recovery delayed in those with chronically elevated baseline cortisol (Lennartsson et al., Psychoneuroendocrinology 2012; PMID: 22119166). For women already in perimenopause with reduced adrenal androgen reserve, this suppression is proportionally more impactful — there's less buffer.

Practical stress reduction strategies that have evidence behind them include:

1. Resistance training 3–4x per week — shown to acutely raise free testosterone and improve androgen sensitivity in middle-aged women.
2. Sleep optimization — testosterone secretion is partially nocturnal and tied to deep sleep stages; even one week of sleep restriction meaningfully reduces androgen output.
3. Adaptogenic herbs — ashwagandha (KSM-66 extract at 300–600mg daily) has been shown in RCTs to reduce cortisol by 27–30% and preserve DHEAS levels under stress conditions (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798).
4. Mindfulness-based stress reduction (MBSR) — demonstrated cortisol-lowering effects in perimenopausal women in controlled trials.
5. Limiting alcohol — even moderate intake suppresses testosterone production and increases SHBG.

Foods That Boost Testosterone in Perimenopause

Diet exerts meaningful influence over androgen levels through multiple pathways: micronutrient availability for testosterone synthesis, insulin signaling, inflammation, and gut-hormone crosstalk. No food will replace a clinical intervention if testosterone is significantly deficient, but nutritional optimization creates the foundation on which hormonal health is built.

Zinc-rich foods: Zinc is a rate-limiting cofactor in testosterone biosynthesis. Deficiency reliably suppresses androgen production, and repletion restores it. Rich sources include oysters (the highest dietary source by far), red meat, pumpkin seeds, and legumes. In men with deficiency, zinc supplementation raised testosterone significantly; the mechanism is conserved in women (Prasad et al., Nutrition 1996; PMID: 8875519).

Cruciferous vegetables: Broccoli, kale, Brussels sprouts, and cauliflower contain indole-3-carbinol (I3C) and its gut-derived metabolite DIM (diindolylmethane), which modulate estrogen metabolism and can reduce SHBG — effectively increasing free testosterone without changing total testosterone.

Healthy fats and cholesterol: Testosterone is a steroid hormone synthesized from cholesterol. Diets very low in fat and cholesterol have been associated with lower androgen levels. Olive oil, avocado, eggs, and fatty fish support the lipid substrate pool for steroid synthesis.

Magnesium-rich foods: Magnesium inhibits SHBG binding, increasing free testosterone availability. Leafy greens, almonds, pumpkin seeds, and dark chocolate are good sources. A 2011 study in men found that magnesium supplementation significantly increased both free and total testosterone after 4 weeks of resistance training (Cinar et al., Biological Trace Element Research 2011; PMID: 21671089).

Vitamin D: Technically a prohormone, vitamin D has nuclear receptors in Leydig-equivalent androgen-producing cells. Deficiency correlates with lower testosterone, and supplementation in deficient individuals improves androgen levels. The intersection of vitamin D and perimenopause is significant — see our piece on what happens to vitamin D in perimenopause for more.

Foods to limit: Ultra-processed foods, refined carbohydrates, and alcohol all raise insulin and cortisol — both of which suppress testosterone synthesis and raise SHBG.

What This Means for Your Formula

Testosterone support in perimenopause isn't about adding exogenous androgens — it's about removing the physiological obstacles that suppress natural production and ensuring the nutrient cofactors for synthesis are present at clinical levels.

Ones evaluates hormonal context from bloodwork and symptom data before recommending any formula. Three ingredients particularly relevant to testosterone dynamics in perimenopause include:

Ashwagandha (KSM-66, 600mg): The most rigorously studied adaptogen for cortisol reduction. By lowering chronically elevated cortisol, KSM-66 reduces HPG axis suppression, allowing adrenal and ovarian androgen production to recover. The 2012 Chandrasekhar RCT (n=64, 60 days) showed a 27.9% reduction in serum cortisol versus placebo (PMID: 23439798). Ones uses the full KSM-66 extract at the clinical dose of 600mg.

Zinc (as zinc bisglycinate): Ones formulas can include zinc at doses calibrated to lab-confirmed deficiency — not a blanket addition for everyone. Zinc bisglycinate is chelated for superior absorption compared to zinc oxide, which is relevant because gut absorption efficiency tends to decrease with age and under chronic stress.

Vitamin D3 + K2 (MK-7): Vitamin D deficiency is common in perimenopausal women and correlates independently with lower free testosterone. Ones pairs D3 with K2 (as MK-7) to support calcium trafficking alongside androgen optimization — since both testosterone and vitamin D interact with bone metabolism.

If bloodwork shows elevated SHBG as the primary driver of low free testosterone, the formula approach shifts accordingly — focusing on magnesium, DIM-adjacent support, and insulin-sensitizing nutrients rather than on adrenal support alone. That's the difference between a personalized protocol and a generic hormone supplement.

Key Takeaways

• Testosterone falls roughly 50% between a woman's peak reproductive years and her early 50s, driven by declining ovarian and adrenal output — not a single perimenopausal event.
• Free testosterone matters more than total testosterone; elevated SHBG can leave you symptomatic even with "normal" lab numbers.
• Low testosterone signs include reduced libido, fatigue, muscle loss, mood changes, and cognitive fog; high testosterone signs include acne, hirsutism, and oily skin.
• Chronic stress is one of the most modifiable drivers of androgen decline — cortisol directly suppresses HPG axis activity and depletes adrenal androgen precursors.
• Diet plays a structural role: zinc, magnesium, vitamin D, and healthy fats are rate-limiting for testosterone synthesis and SHBG regulation.
• Personalized supplementation — calibrated to your actual bloodwork and symptom picture — is more effective than generic hormone support blends. Ones uses lab data to determine which deficiencies are actually driving your androgen picture before building a formula.